미국의 약국 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 유형별, 소유자별, 부문 예측(2025-2033년)

U.S. Pharmacy Market Size & Trends:

The U.S. pharmacy market size was estimated at USD 732.44 billion in 2024 and is projected to reach at USD 1,707.02 billion by 2033, growing at a CAGR of 9.91% from 2025 to 2033. The growth is attributed to the rising prevalence of chronic diseases, the high utilization of prescription drugs, and the increasing elderly population in the country.

A report from the 2023 American Heart Association (AHA) indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure.

U.S. Pharmacy Market Report Segmentation

This report forecasts revenue growth, country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. pharmacy market report based on type, product type, and ownership.

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Retail chains (e.g., Walgreens, CVS)
• Supermarket pharmacies
• Health system/hospital pharmacies
• Independent pharmacies
• Mail-order pharmacies
• Specialty / central fill pharmacies
• Long-term care and defense-related pharmacies
• ePharmacy
• Others
• Product Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Prescription
• OTC
• Ownership Outlook (Revenue, USD Billion, 2021 - 2033)
• Chain
• Independent

Table of Contents

Chapter 1. Report Scope & Research Methodology

• 1.1 Market Segmentation
  • 1.1.1 Segment Definition
    • 1.1.1.1 Product Type
    • 1.1.1.2 Type
• 1.2 Estimates and Forecast Timeline
• 1.3 Research Methodology
  • 1.3.1 Information Procurement
  • 1.3.2 Purchased Database
  • 1.3.3 Gvr's Internal Database
  • 1.3.4 Secondary Sources
  • 1.3.5 Primary Research
  • 1.3.6 Details Of Primary Research
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Three Pillars of Market Estimation
    • 1.6.1.1 Secondary Market Research
    • 1.6.1.2 Primary Market Intelligence
      • 1.6.1.2.1 In-Depth Interviews (IDIs)
      • 1.6.1.2.2 Online Survey Program
  • 1.6.2 Market Modeling & Forecasting
    • 1.6.2.1 Model 1: Volume-Price Analysis
      • 1.6.2.1.1 Step 1: Prescription volume estimation
      • 1.6.2.1.2 Channel-Wise Methodology
        • 1.6.2.1.2.1 Retail Chains (CVS, Walgreens, etc.)
        • 1.6.2.1.2.2 Supermarket Pharmacies (Kroger, Albertsons, Publix)
        • 1.6.2.1.2.3 Health System / Hospital Outpatient Pharmacies
        • 1.6.2.1.2.4 Independent Pharmacies
        • 1.6.2.1.2.5 Mail-Order Pharmacies
        • 1.6.2.1.2.6 Specialty / Central Fill Pharmacies
        • 1.6.2.1.2.7 Long-Term Care (LTC) and Defense-Related Pharmacies
        • 1.6.2.1.2.8 ePharmacies (Amazon, Capsule, Hims & Hers, etc.)
        • 1.6.2.1.2.9 Other Channels
        • 1.6.2.1.2.10 Aggregation & Triangulation
      • 1.6.2.1.3 Step 2: Determining Average Realized Price (ARP)
      • 1.6.2.1.4 Step 2: OTC Revenue
    • 1.6.2.2 Model 2: Company Market Share Analysis
      • 1.6.2.2.1 Step 1: Public Filings
      • 1.6.2.2.2 Step 2: Private & Independent Estimates
      • 1.6.2.2.3 Step 3: Market Share Allocation
    • 1.6.2.3 CAGR/Forecasting Calculations & Assumptions
      • 1.6.2.3.1 Key Forecasting Drivers and Weights
      • 1.6.2.3.2 Scenario Framework (2025-2033)
      • 1.6.2.3.3 Factor-Based Impact Assessment
  • 1.6.3 Estimation Process: Pharmacy Type Split By Catchment Area
    • 1.6.3.1 Data Sources
    • 1.6.3.2 Estimation Process
  • 1.6.4 Estimation Process: Pharmacy Type Split By Product Form
  • 1.6.5 Company-Level Metric's Estimation
    • 1.6.5.1 Financial Performance
      • 1.6.5.1.1 2024 Revenue & EBITDA (Pharmacy-Only)
      • 1.6.5.1.2 5-Year Forecast of Revenue & EBITDA
      • 1.6.5.1.3 Balance Sheet Health Indicators
    • 1.6.5.2 Volumes & Operations
      • 1.6.5.2.1 2024 Total Prescriptions; 5-Year Rx Forecast
      • 1.6.5.2.2 % Fulfilled via Central Fill; Volumes Split by Catchment Area
• 1.7 List of Secondary Sources
• 1.8 List of Abbreviations
• 1.9 Research Objectives
  • 1.9.1 Objective - 1
  • 1.9.2 Objective - 2
  • 1.9.3 Objective - 3

Chapter 2. Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Outlook - I
• 2.3 Segment Outlook- II
• 2.4 Competitive Scenario

Chapter 3. U.S. Pharmacy Market - Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
  • 3.1.2 Related Market Outlook
    • 3.1.2.1 U.S. pharmacy benefit management market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Increasing prevalence of chronic diseases
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Expanding health insurance coverage
    • 3.2.1.4 Increasing demand for specialty drugs
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Product recalls and lawsuits
    • 3.2.2.2 Lack of trained staff
  • 3.2.3 Market Opportunity Analysis
  • 3.2.4 Market Challange Analysis
• 3.3 Regulatory Scenario & Reimbursement Outlook
  • 3.3.1 Regulatory Scenario
  • 3.3.2 Reimbursement Scenario
• 3.4 Business Environment Analysis Tools
  • 3.4.1 Porter's Five Forces Analysis
  • 3.4.2 Pestle Analysis

Chapter 4. U.S. Pharmacy Market: Product Type Estimates & Trend Analysis

• 4.1 U.S. Pharmacy Market: Product Type Segment Dashboard
• 4.2 Product Type Movement & Market Share Analysis, 2024 & 2033
• 4.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Product Type (USD Billion)
  • 4.3.1 Prescription
    • 4.3.1.1 Prescription market, 2021-2033 (USD Billion)
  • 4.3.2 Over-the-Counter (OTC)
    • 4.3.2.1 OTC market, 2021-2033 (USD Billion)

Chapter 5. U.S. Pharmacy Market: Type Estimates & Trend Analysis

• 5.1 U.S. Pharmacy Market: Type Segment Dashboard
• 5.2 Type Movement & Market Share Analysis, 2024 & 2033
• 5.3 U.S. Pharmacy Market Size & Forecast and Forecasts, By Type, 2021 - 2033 (USD Billion)
• 5.4 U.S. Pharmacy Market: Estimated Number of Pharmacies, By Type, 2021 - 2033 (Unit)
• 5.5 U.S. Pharmacy Market: Estimated Prescription Volume, By Type, 2021 - 2033 (Million)
• 5.6 U.S. Pharmacy Market: Estimated Prescription Volume, By Catchment Area, 2024 (%)
• 5.7 U.S. Pharmacy Market: Estimated Prescription Volume, By Filled Prescriptions (TRx), 2024 (%)
  • 5.7.1 Retail Chains
    • 5.7.1.1 Retail chains market, 2021 - 2033 (USD Billion)
  • 5.7.2 Supermarket Pharmacies
    • 5.7.2.1 Supermarket pharmacies market, 2021 - 2033 (USD Billion)
  • 5.7.3 Health System / Hospital Pharmacy
    • 5.7.3.1 Health system / Hospital pharmacy market, 2021 - 2033 (USD Billion)
  • 5.7.4 Independent Pharmacies
    • 5.7.4.1 Independent pharmacies market, 2021 - 2033 (USD Billion)
  • 5.7.5 Mail-Order Pharmacies
    • 5.7.5.1 Mail-order pharmacy market, 2021 - 2033 (USD Billion)
  • 5.7.6 Specialty / Central Fill Pharmacies
    • 5.7.6.1 Specialty / central fill pharmacies market, 2021 - 2033 (USD Billion)
  • 5.7.7 Long-Term Care And Defense-Related Pharmacies
    • 5.7.7.1 Long-term care and defense-related pharmacies market, 2021 - 2033 (USD Billion)
  • 5.7.8 Epharmacy
    • 5.7.8.1 ePharmacy market, 2021 - 2033 (USD Billion)
  • 5.7.9 Others
    • 5.7.9.1 Others market, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Pharmacy Market Competitive Analysis

• 6.1 Company Categorization
• 6.2 Estimated Company Market Share Analysis, 2024
  • 6.2.1 CVS Pharmacy
    • 6.2.1.1 Company Overview
    • 6.2.1.2 Financial Performance
      • 6.2.1.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.1.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.1.2.3 Balance sheet health metrics (2024)
    • 6.2.1.3 Volumes & Operations
      • 6.2.1.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.1.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.1.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.1.4 Value Chain Position
      • 6.2.1.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.1.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.1.5 Central Fulfillment (if used/planned)
      • 6.2.1.5.1 Strategy
      • 6.2.1.5.2 Requirements
      • 6.2.1.5.3 Technology provider(s) and hardware/automation
      • 6.2.1.5.4 Partnerships
    • 6.2.1.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.2 Walgreens Boots Alliance, Inc.
    • 6.2.2.1 Company Overview
    • 6.2.2.2 Financial Performance
      • 6.2.2.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.2.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.2.2.3 Balance sheet health metrics (2024)
    • 6.2.2.3 Volumes & Operations
      • 6.2.2.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.2.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.2.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.2.4 Value Chain Position
      • 6.2.2.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.2.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.2.5 Central Fulfillment (if used/planned)
      • 6.2.2.5.1 Strategy
      • 6.2.2.5.2 Requirements
      • 6.2.2.5.3 Technology provider(s) and hardware/automation
      • 6.2.2.5.4 Partnerships
    • 6.2.2.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.3 Scriptco Pharmacy
    • 6.2.3.1 Company Overview
    • 6.2.3.2 Financial Performance
      • 6.2.3.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.3.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.3.2.3 Balance sheet health metrics (2024)
    • 6.2.3.3 Volumes & Operations
      • 6.2.3.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.3.3.2 % of prescriptions fulfilled via central fill (2024)
    • 6.2.3.4 Value Chain Position
      • 6.2.3.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.3.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.3.5 Central Fulfillment (if used/planned)
      • 6.2.3.5.1 Strategy
      • 6.2.3.5.2 Requirements
      • 6.2.3.5.3 Technology provider(s) and hardware/automation
      • 6.2.3.5.4 Partnerships
    • 6.2.3.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.4 Walmart Pharmacy
    • 6.2.4.1 Company Overview
    • 6.2.4.2 Financial Performance
      • 6.2.4.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.4.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.4.2.3 Balance sheet health metrics (2024)
    • 6.2.4.3 Volumes & Operations
      • 6.2.4.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.4.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.4.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.4.4 Value Chain Position
      • 6.2.4.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.4.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.4.5 Central Fulfillment (if used/planned)
      • 6.2.4.5.1 Strategy
      • 6.2.4.5.2 Requirements
      • 6.2.4.5.3 Technology provider(s) and hardware/automation
      • 6.2.4.5.4 Partnerships
    • 6.2.4.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.5 Avita Pharmacy
    • 6.2.5.1 Company Overview
    • 6.2.5.2 Financial Performance
      • 6.2.5.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.5.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.5.2.3 Balance sheet health metrics (2024)
    • 6.2.5.3 Volumes & Operations
      • 6.2.5.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.5.3.2 % of prescriptions fulfilled via central fill (2024)
    • 6.2.5.4 Value Chain Position
      • 6.2.5.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.5.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.5.5 Central Fulfillment (if used/planned)
      • 6.2.5.5.1 Strategy
      • 6.2.5.5.2 Requirements
      • 6.2.5.5.3 Technology provider(s) and hardware/automation
      • 6.2.5.5.4 Partnerships
    • 6.2.5.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.6 The Kroger Co.
    • 6.2.6.1 Company Overview
    • 6.2.6.2 Financial Performance
      • 6.2.6.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.6.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.6.2.3 Balance sheet health metrics (2024)
    • 6.2.6.3 Volumes & Operations
      • 6.2.6.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.6.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.6.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.6.4 Value Chain Position
      • 6.2.6.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.6.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.6.5 Central Fulfillment (if used/planned)
      • 6.2.6.5.1 Strategy
      • 6.2.6.5.2 Requirements
      • 6.2.6.5.3 Technology provider(s) and hardware/automation
      • 6.2.6.5.4 Partnerships
    • 6.2.6.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.7 Albertsons Companies, Inc.
    • 6.2.7.1 Company Overview
    • 6.2.7.2 Financial Performance
      • 6.2.7.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.7.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.7.2.3 Balance sheet health metrics (2024)
    • 6.2.7.3 Volumes & Operations
      • 6.2.7.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.7.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.7.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.7.4 Value Chain Position
      • 6.2.7.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.7.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.7.5 Central Fulfillment (if used/planned)
      • 6.2.7.5.1 Strategy
      • 6.2.7.5.2 Requirements
      • 6.2.7.5.3 Technology provider(s) and hardware/automation
      • 6.2.7.5.4 Partnerships
    • 6.2.7.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.8 Costco Wholesale Corporation.
    • 6.2.8.1 Company Overview
    • 6.2.8.2 Financial Performance
      • 6.2.8.2.1 Revenue (pharmacy-only where available/estimable), 2024 - 2029 (USD Million)
      • 6.2.8.2.2 EBITDA (%) & EBITDA Margin (2024)
      • 6.2.8.2.3 Balance sheet health metrics (2024)
    • 6.2.8.3 Volumes & Operations
      • 6.2.8.3.1 Estimated prescription volumes; 2024 - 2029 (Million)
      • 6.2.8.3.2 % of prescriptions fulfilled via central fill (2024)
      • 6.2.8.3.3 % of prescriptions fulfilled by catchment areas (2024)
    • 6.2.8.4 Value Chain Position
      • 6.2.8.4.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.8.4.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.8.5 Central Fulfillment (if used/planned)
      • 6.2.8.5.1 Strategy
      • 6.2.8.5.2 Requirements
      • 6.2.8.5.3 Technology provider(s) and hardware/automation
      • 6.2.8.5.4 Partnerships
    • 6.2.8.6 Strategy Mapping/ Major Deals & Strategic Alliances Analysis
  • 6.2.9 Sam's West, Inc.
    • 6.2.9.1 Company Overview
    • 6.2.9.2 Value Chain Position
      • 6.2.9.2.1 Current wholesaler(s), distributor(s), and GPO affiliations (if applicable)
      • 6.2.9.2.2 Ownership (public/private), parent/subsidiaries, recent M&A divestments
    • 6.2.9.3 Central Fulfillment (if used/planned)
      • 6.2.9.3.1 Strategy
      • 6.2.9.3.2 Requirements
      • 6.2.9.3.3 Technology provider(s) and hardware/automation
      • 6.2.9.3.4 Partnerships
    • 6.2.9.4 Strategy Mapping/ Major Deals & Strategic Alliances Analysis